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Low and middle income countries (LMIC)
Antimicrobial stewardship
A B S T R A C T
The dissemination of COVID-19 around the globe has been followed by an increased consumption of
antibiotics. This is related to the concern for bacterial superinfection in COVID-19 patients. The
identification of bacterial pathogens is challenging in low and middle income countries (LMIC), as there
are no readily-available and cost-effective clinical or biological markers that can effectively discriminate
between bacterial and viral infections. Fortunately, faced with the threat of COVID-19 spread, there has
been a growing awareness of the importance of antimicrobial stewardship programs, as well as infection
prevention and control measures that could help reduce the microbial load and hence circulation of
pathogens, with a reduction in dissemination of antimicrobial resistance. These measures should be
improved particularly in developing countries. Studies need to be conducted to evaluate the worldwide
evolution of antimicrobial resistance during the COVID-19 pandemic, because pathogens do not respect
borders. This issue takes on even greater importance in developing countries, where data on resistance
patterns are scarce, conditions for infectious pathogen transmission are optimal, and treatment resources
are suboptimal.
© 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Antibiotics and antimicrobial resistance in the COVID-19 era
Increased antibiotic use leads to the emergence and dissemi-
nation of antimicrobial resistance (AMR), which is a major global
health challenge. One of the main recommendations to combat this
problem is to optimize antibiotic use by ensuring that the
appropriate antibiotic is administered at the correct dose, for
the correct duration, and in a manner that ensures the best
outcome and limits side effects and AMR. These are, in fact,
hallmarks of antimicrobial stewardship programs (Dryden et al.,
2011). Nevertheless, since the beginning of the COVID-19
pandemic, there has been growing concern for a potential rise
in AMR secondary to increased antibiotic prescription for COVID-
19 patients (Rawson et al., 2020a). The aims of this article are to
describe how this viral pandemic has caused increased antibiotic
use and also the risk of increasing AMR, particularly in low and
middle income countries (LMIC).
Antimicrobial resistance
AMR is a grave and pressing public health problem. It has been
estimated that by 2050, AMR will be responsible for the death of 10
million people and, furthermore, will cost as much as US$ 100
trillion (O’Neill, 2016). The spectrum of resistance varies widely
from region to region. For example, using data from the 2019
Global Antimicrobial Resistance and Use Surveillance System
(GLASS), it can be seen that resistance to ciprofloxacin for urinary
tract infections ranges from 8.4% to 92.9% for Escherichia coli, and
from 4.1% to 79.4% for Klebsiella pneumoniae (World Health
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Organization, 2020a). In high income countries (HIC), AMR is a
serious challenge. In the US, 2.8 million antibiotic-resistant
infections are reported each year, with more than 35 000 deaths
(US Centers for Disease Control and Prevention (CDC), 2019).
Estimating the extent of AMR in LMIC is hampered by limited data:
AMR data are unavailable for 42.6% of countries in Africa (Tadesse
et al., 2017).
Bacterial co-infection and COVID-19
A study conducted in January 2020 in an adult infectious
disease unit in China, found that 71% of the patients hospitalized
for COVID-19 had received antibiotics despite a confirmed bacterial
co-infection rate of only 1% (Chen et al., 2020). Another study in
two hospitals in China reported that 95% of COVID-19 patients had
been placed on antibiotic regimens even though a secondary
bacterial infection was only found in 15% of the patients (Zhou
et al., 2020a). However, in a study in the UK, blood cultures in early
2020 were positive in 3.2% of cases during the first 5 days of
admission, and beyond this, the rate increased to 6.1%. In
respiratory samples, a pathogenic bacterium could be identified
in 34.8% of cases (Hughes et al., 2020). all 19 patients had a
bacterial infection: Acinetobacter baumannii for 90% and Staphylo-
coccus aureus for 10% (Sharifipour et al., 2020). It appears,
therefore, that the prevalence of bacterial infection may vary
depending on the country in question and also on the time after the
onset of symptoms at which the samples are obtained. It seems
clear that decisions on antibiotic therapy must be informed by
regional epidemiological trends and the specific circumstances of
the patient treated.
The initial impression of high antibiotic consumption during
this viral pandemic was influenced by early reports from Wuhan,
China indicating that 50% of patients who died from COVID-19 had
a secondary bacterial infection (Zhou et al., 2020a). This
phenomenon is consistent with reviews of autopsy series and
post-mortem cultures from the 1918 influenza pandemic, reveal-
ing that most victims had concurrent bacterial pneumonia
(Morens et al., 2008). Some preliminary findings of studies
focusing on co-infections in COVID-19 patients showed that the
bacteria most frequently isolated from induced sputum and/or
bronchoalveolar lavage from COVID-19 patients were Mycoplasma
pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae.
This suggests a difference in the co-infecting pathogens of COVID-
19 patients from those commonly observed in co-infected patients
with influenza (e.g., Streptococcus pneumoniae, S. aureus, and
Streptococcus pyogenes) (Lansbury et al. 2020). Growing evidence
suggests, therefore, that antimicrobial stewardship measures
specific for COVID-19 patients should be preferentially followed,
rather than relying on existing empiric treatment guidelines for
influenza patients with secondary bacterial infections.
However, in the face of this evolving pandemic, lessons can be
drawn from previous severe outbreaks of coronavirus (severe acute
respiratory syndrome coronavirus (SARS-CoV)) to inform antimi-
crobial management of secondary co-infections in COVID-19
patients, as well as infection prevention control measures based
on AMR. For example, the term super-spreader has been used for
settings like hospitals, cruise ships, etc.; i.e., for events where there
is an important movement of the population leading to high rates
of transmission (Cave, 2020). Past SARS-CoV outbreaks have
shown that hospitalized patients with bacterial co-infections can
be super-spreaders of resistant bacteria, each individual possibly
infecting more than 10 other people (Wi et al., 2020). In the case of
COVID-19, it has been demonstrated that 80% of contaminations
are related to 20% of subjects. It remains unknown whether severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
associated with the same pattern of spread of resistant bacteria
as SARS-CoV (Cave, 2020). Nonetheless, this is an important
observation to keep in mind to reduce the risk of AMR infections
and hospital transmission, particularly in LMIC where hospital
infection prevention and control measures are often sub-optimal
(Alp and Damani, 2015).
Challenges of bacterial identification in patients with
pneumonia
As in the case of most infections, the initial choice of antibiotics
in COVID-19 patients is often empiric (Huang et al., 2020). Huang
et al. reported that while 98% of COVID-19 patients had bilateral
lung involvement on chest X-ray, only 28% of patients had enough
sputum production to perform a Gram stain or culture (Huang
et al., 2020). This scarcity of sputum production in these patients is
further complicated by the fact that the identification of pathogens
from sputum samples in patients with pneumonia is overall
modest and yields results in only 23% of cases (Saldías Peñafiel
et al., 2018). Moreover, concerns about aerosol-generating
procedures (i.e., deep airway suctioning or bronchoalveolar lavage)
further limit the ability to obtain satisfactory sputum samples for
bacterial identification and other microbiological studies (Van
Doremalen et al., 2020). However, if personal protective equipment
is adequate, the proscription of important diagnostics or thera-
peutic procedures should be reconsidered (Agalar and Engin,
2020).
Synergy between viral and bacterial pathogens
Despite some preliminary evidence, it is still unclear whether
similar synergies exist between SARS-CoV-2 and specific bacterial
infections as exist with influenza (Rowe et al., 2019). It has been
shown that respiratory viral infections may alter innate immune
function in affected pulmonary tissue, promoting bacterial growth:
macrophages are overwhelmed by this increased burden of
apoptotic cells and thus become limited in their capacity to
phagocytose bacteria (Morgan et al., 2018). It has also been
observed that both dendritic cells and macrophages have
diminished antigen-presenting ability following bacterial and
viral infections, which is linked to an immunosuppressive
microenvironment involving T (Treg) cells and the cytokine
transforming growth factor beta (TGF-β) – a form of immunopar-
alysis (Roquilly et al., 2017). In addition, the initial immune
response to a viral lung infection modifies the respiratory tract
microbiome, which can, in turn, undermine immune defenses
against infectious pathogens (Hanada et al., 2018). Other inciting
mechanisms following viral illnesses include altered epithelial
cells that disrupt the mucocilliary clearance and mucus thickening
impairing the movement of immune cells (Manohar et al., 2020). In
the particular setting of SARS-CoV-2 infection, fluid and pus-filled
pulmonary alveoli create a nutritive environment for bacteria such
as P. aeruginosa and S. aureus (Manohar et al., 2020) [Au?1].
If such synergy is proven, the administration of antibiotics
would be useful and understandable. In fact, treatment with an
antibiotic (azithromycin) and antimalarial (hydroxychloroquine)
showed in vitro effectiveness against SARS-CoV-2 and these agents
have been used (Andreani et al., 2020). However, although this
combination therapy showed early promise, the results of
subsequent clinical studies have been equivocal: some have found
no beneficial effect (Magagnoli et al. 2020), while others have
indicated that hydroxychloroquine yields a mortality reduction of
66%, rising to 71% when used in combination with azithromycin
(Arshad et al., 2020). Furthermore, while some studies have found
potential cardiac toxicity of hydroxychloroquine combined with
azithromycin (Nguyen et al., 2020), others have found no report of
torsade de pointes or fatal dysrhythmias, and have commented
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that clinicians have seldom needed to discontinue therapy (Saleh
et al., 2020). Currently there is no definitive evidence on the clinical
benefits of chloroquine or hydroxychloroquine, while there is
evidence of the potential harm (Tang et al., 2020).
Clinical trials are underway that may provide answers to the
potential contribution of different therapies in the treatment of
COVID-19. An example is the Solidarity Trial, an international study
conducted by the World Health Organization (WHO), which is
based on the principle of repurposing drugs previously used for
other indications: remdesivir, hydroxychloroquine, lopinavir/
ritonavir, and interferon (Anon, 2020b) . Nevertheless, on October
15, 2020, the WHO published interim results of the Solidarity Trial,
which showed that the four treatments evaluated had no benefit
on overall mortality, the initiation of ventilation, or the duration of
hospital stay in hospitalized patients (Anon, 2020c). The results
from other clinical trials should help guide the choice of treatment
and reduce the use of antibiotics and other drugs that have not
been proven to be effective for COVID-19 patients.
Challenges of the choice of antibiotics for COVID-19 patients in
LMIC
If the use of antibiotics to treat nosocomial bacterial co-
infections is justified by the risk of requiring invasive mechanical
ventilation (Rawson et al. 2020b), the paucity of ventilators in LMIC
minimizes this risk and should therefore greatly reduce unneces-
sary antimicrobial use (Losonczy et al., 2019). However, even as
short-term peripheral venous catheters can be associated with
higher rates of bloodstream infections in LMIC than in HIC
(Rosenthal et al. 2020), there is a risk that the increasing number of
hospitalized patients with COVID-19 may lead to increased
reliance on antibiotics to fight nosocomial catheter-associated
infections. The implementation of infection prevention and control
measures could help mediate this risk, as well as antimicrobial
consumption (Phan et al., 2020). It would be revealing to conduct
studies on bacterial co-infections in COVID-19 patients in LMIC,
since previous studies have revealed that, for the same bacterial
pathogens, differences exist between HIC and LMIC regarding
populations at risk, clinical manifestations, frequency of pathogen
distribution, and antibiotic susceptibility (Aston, 2017). The threat
of COVID-19 may, in fact, offer opportunities in LMIC to implement
antimicrobial stewardship programs in line with WHO guidelines:
education and training of an antimicrobial stewardship team,
development of clinical guidelines, surveillance of resistance and
antibiotic use (World Health Organization, 2019).
Optimization of antibiotic use in COVID-19 patients from LMIC
LMIC might be more impacted by COVID-19-associated
antibiotic resistance for a number of reasons, including reliance
on empiric therapy due to the lack of clinical microbiology
laboratory capacity, deficiencies in infection prevention and
control measures, and systemic stress making the implementation
of new practices more difficult. There are a number of possible
strategies to reduce excessive antimicrobial use and the resultant
antibiotic resistance. The straightforward strategy promoted by
most ministries of health could limit antibiotic use: if you have a
fever or symptoms similar to flu, stay at home, drink liquids, and
take paracetamol. Aside from the obvious public health benefit of
this approach, such behavior could reduce antibiotic consumption,
since patients seeking care for acute respiratory illnesses may
receive unnecessary antibiotics in 41% of cases (Havers et al., 2018).
Rapid viral testing could also further reduce the unwarranted
prescription of antibiotics in LMIC, as it has been shown that those
who test positive for influenza are 50% less likely to receive
antibiotics (Tillekeratne et al., 2015). Unfortunately, in developing
countries, antibiotics are often sold in the street without
prescription, allowing people to purchase them with the intent
of preventing or self-treating COVID-19 or other viral infections,
leading to inappropriate use in the setting of non-bacterial
infections.
As bacterial co-infection in COVID-19 patients may be less than
15% (Zhou et al., 2020b), it would be prudent to reserve antibiotics
for patients with suspected or severe COVID-19 manifestations.
Testing for COVID-19 in respiratory patients may therefore be an
effective way to limit antibiotic use during the pandemic (Getahun
et al., 2020). This approach is recommended by the WHO to combat
the pandemic. However, this policy assumes that the country has
the capacity to conduct testing and the means to enforce the
isolation of infected patients.
Challenges of the traditional measures of the test and isolate
strategy in LMIC
Mass viral testing and timely screening has proven challenging
even for HIC, and it is even more so in LMIC (“Coronavirus Testing
Labs Again Lack Key Supplies” – The New York Times). The fierce
and unfair competition between LMIC and HIC for limited stocks of
reagents and protective equipment has created additional dis-
parities and barriers to implementing strategies to prevent spread,
especially in LMICs (“In Scramble for Coronavirus Supplies, Rich
Countries Push Poor Aside” – The New York Times”). In addition,
fragile healthcare infrastructure in many limited resource coun-
tries makes it difficult to apply basic preventive measures such as
inpatient hospital isolation. Isolation rooms are severely limited in
41% of hospitals in LMIC, thereby creating the risk of exposure for
patients without COVID-19 (Alp et al., 2011). In addition, the
crowded home environments found in LMIC make any attempt to
isolate infected patients at home illusory (“Tracking Improvement
in the Lives of Slum Dwellers” Prepared by the PSUP Team Nairobi.
Printing: UNON, Publishing Services Section, Nairobi, ISO
14001:2004-certified D1 No: 15-02822/200 copies/jw). The
inadequate resources for testing for COVID-19 and the limited
capacity to isolate those infected raises the question of the
practicality of adopting a mass testing strategy in developing
countries.
In this case, it is important to develop alternative response
strategies. Aggressive screening of suspected cases, contact-
tracing, and the creation of emergency ad hoc isolation sites,
etc., are very costly and complex undertakings requiring high levels
of funding. Furthermore, contact-tracing is probably more useful at
the beginning of an outbreak than later and can be very difficult to
execute when there is a high number of daily community
transmissions. However, these measures can be effective at
limiting the number of people infected by SARS-CoV-2, and hence,
possibly receiving unnecessary antibiotics. The development and
validation of treatment algorithms incorporating clinical signs and
possibly selected biological markers as well, could help clinicians
decide on antibiotic use.
Discrimination between viral and bacterial co-infection to
avoid unnecessary antibiotics
While the symptomology described in COVID-19 generally
overlaps with other respiratory infectious diseases, some specific
symptoms/signs described can be used to support the diagnosis of
COVID-19 (e.g., anosmia). The presence of other clinical hallmarks
such as fever, persistent cough, diarrhea, fatigue, abdominal pain,
and loss of appetite can further support this diagnosis (Menni et al.,
2020). While some common biomarkers, such as C-reactive protein
(CRP) and procalcitonin, have not proven helpful at discriminating
between patients presenting with COVID-19 and those with
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additional bacterial co-infection, they provide some value in
assessing disease severity, and could be useful for predicting the
prognosis (Hu et al. 2020). Ongoing research is continuing to define
the role of these tools in clinical decision-making (Rawson et al.
2020a; Lansbury et al., 2020).
Contribution of antimicrobial stewardship programs and
infection prevention control to fight antimicrobial resistance in
LMIC
The WHO has developed guidelines for the clinical manage-
ment of COVID-19 that do not endorse the prescription of
antibiotics for patients with suspected or confirmed mild
COVID-19 with a low suspicion of a bacterial infection. However,
for suspected or confirmed severe COVID-19, the use of empiric
antimicrobials is recommended in order to treat all likely
pathogens (Anon, 2020b). Finally, although there is not yet an
optimal strategy for combating global COVID-19, providers in LMIC
should try to establish and/or strengthen antimicrobial steward-
ship as well as infection prevention and control programs to reduce
the emergence and dissemination of AMR (Septimus, 2018).
The type of antimicrobial stewardship program that will work will
be very context-specific, but could include education about AMR, the
development of guidelines, infection prevention and control guide-
lines, contributions from an infectious disease consultant at the
hospital level, intravenoustooralswitchtherapy, rulesandregulations
for antibiotic quality control, upgraded microbiology laboratory
capacity, the development of a national action plan, and the
implementation of an infection prevention control program (Cox
et al., 2017). The choice of measures to enact will depend greatly on
local factors, such as available human and economic resources, and
infrastructure. Whatever the choice, interventions must be evaluated
to demonstrate improvement and also guide further decisions.
Ultimately, the choice must have an impact on the real world of
people living in the resource-constrained countries, because some-
times there is a gap between the development and implementation of
public health policyand the actual benefits accruing to the population.
Dialogue between researchers and policy-makers could help fill this
gap. In this perspective, the scope of research undertaken, as well as
the researchers themselves, must recognize the financial constraints
and limitations in human resources, bureaucratic support, and
infrastructure that political leaders and decisions-makers in LMIC
face, and these realities should be integrated into their work and
recommendations. It is also essential to evaluate the cultural
environment in which the policies are being implemented. That is
why it is very important to facilitate a transparent and honest dialogue
between research, political, and executive teams (Cave, 2020).
Ultimately, the strategies discussed here could contribute to
saving lives and reducing the economic costs of healthcare. In
addition, an unanticipated but beneficial consequence of the
COVID-19 pandemic is a heightened awareness about general
infection prevention and control measures, such as hand hygiene,
surface disinfection, and social distancing, which may help reduce
the long-term dissemination of AMR. Finally, it is of the utmost
importance in LMIC to continue to conduct studies on antimicro-
bial consumption and the prevalence of bacterial co-infection, with
susceptibility profiles whenever possible, to follow the evolution of
AMR in these countries during the COVID-19 pandemic. The results
of these studies could help to define the best strategies to use in
settings with limited laboratory capacity in order to choose
rational empiric antimicrobial therapy.
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